At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In our oncology focus month, Ryan McGuire takes a look at the impact of clinical development on cancer drug prices and the factors involved in the current improved success rate for cancer treatments.

Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S.Seasoned Team to Drive Forward ...

Hong Kong director and photographer Yonfan is finally getting the recognition he deserves, with mainland censors deeming his Crossing Years docu about the late artist fit for the public.

Tiny circles called ecDNA are critical in cancer development and drug resistance. An international team publishes landmark studies detailing new findings and potential therapies.

Special award luncheon and discussion with Ian Urbina of The Outlaw Ocean Project, winners of the 2024 Osborn Elliott Prize for Excellence in Journalism on Asia. Free preview screening! In Mumbai, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...